Can Airflow Limitation in Chronic Obstructive Pulmonary Disease (COPD) be Reversible by Drugs?

Critical combination of various approved drugs in management for patients suffering with COPD.

Completed

Looking for future studies?

Key information

Conditions

Chronic Obstructive Pulmonary Disease Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

22 year–86 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Research Center of Chemical Injuries, Baqiyatallah Medical Sciences University, Mollasadra St,

Tehran, 19945-546, Iran

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

current or past smoker COPD

Exclusion criteria

history of significant occupational or other environmental exposures or a connective tissue disease

Treatment and study plan

Macrolid, Theophylline, Inhaler Corticosteroids

Drug

we have no permission to include them in detail because of privacy policy of mentioned journal for publication

Primary outcomes

15% increasing in forced expiratory volume in 1 second

Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Baqiyatallah Medical Sciences University

Other

Registry information

Official study title

Combination of Approved Drug in COPD

Important dates

Study start: 2008
Primary completion: 2009
Study completion: 2009
First posted: Nov 9, 2009
Registry last updated: Nov 9, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed